Particular caution is required when using the drug There are no special precautions required
Do not assume listing is a foregone conclusion
Stories like Mark's are becoming increasingly common, especially among our clients who are active, driven, and looking for long-term solutions
AOD-9604 FDA Approval History At a glance FDA approval status / Never approved for any indication in the United States NDA filing history / No New Drug Application has ever been submitted to FDA Chemical identity / Synthetic peptide corresponding to amino acids 176-191 of human growth hormone, with a tyrosine residue added at the C-terminus Developer / Metabolic Pharmaceuticals Ltd (Melbourne, Australia), now defunct Clinical trial outcome / Phase IIb trial (2007) failed to meet primary efficacy endpoint for obesity FDA compounding status / Placed on Category 2 list
In diet-induced obesity (DIO) models, NNMT loss-of-function and selective small-molecule inhibitors reduce white adipose mass and improve metabolic parameters without overt toxicity, positioning NNMT as a tractable target for metabolic-disease research [24]
Always read the label on the actual package before using products for the most current information
